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Introduction
Aplastic anemia is a rare and potentially fatal bone marrow disease which can develop at any stage of life and which is characterized by peripheral cytopenia in at least two of the three blood lineages and marrow hypoplasia . They are composed of long stretches of repetitive TTAGGG sequences which are bound by an array of proteins known as shelterins (TRF1, TRF2, TIN2, RAP1, TPP1 and POT1) 5 which are important for telomere protection by preventing telomere fusions and telomere fragility. Telomerase is the enzyme capable of de novo synthesis of telomeric repeats. Telomerase activity is high at the blastocyst stage where telomere length (TL) is determined for a given individual 6, 7 . Thereafter telomeres progressively shorten throughout life due to the down regulation of telomerase and the loss of telomeric sequences associated to the replication of DNA ends with every cell division.
Consequently, cells reaching a critical short telomere length enter into cellular senescence [8] [9] [10] [11] . In contrast to most somatic cells, adult stem cells retain basal telomerase activity which leads to decelerated telomere attrition in these compartments, although eventually they also show telomere shortening associated with the aging process 12 . Conversely, impaired telomerase function, for instance by virtue of Tert haploinsufficiency, leads to accelerated telomere shortening in the stem cell compartments which prematurely limits HSC proliferation potential and tissue renewal capacity, leading to the onset of different diseases. Thus, tissues with a high proliferative index such as the hematopoietic system are particularly affected by lower than normal telomerase levels 13 . One of the most frequent telomere syndromes is dyskeratosis congenita (DKC), clinically defined by a triad of abnormal nails, reticular skin pigmentation, and oral leukoplakia 14, 15 . The most severe complication however, in ~80% of DKC patients, is the development of severe aplastic anemia 14, 16 (since we exclusively study effects in the hematopoietic compartment, we will use the term aplastic anemia hereafter). Interestingly, both DKC and aplastic anemia are characterized by premature telomere shortening. This is either caused by impaired telomere maintenance due to mutations affecting proper telomerase function, or in the case of autoimmune-mediated aplastic anemia, by the increased cell turnover and hyperproliferation to compensate for HSC depletion. Treatment options for aplastic anemia include stem cell transplants and immunosuppressive therapy 17 . Interestingly, for more than 5 decades already, testosterone derivatives like danazol or oxymetholone have been given to aplastic anemia patients and such hormone therapies frequently induced remission 18, 19 . The underlying mechanism for treatment response in autoimmune triggered aplastic anemia remained unclear to date. Interestingly, more recent studies demonstrated that sex hormones act on the Tert gene to increase telomerase expression in vitro 20, 21 . With this in mind, here we set out to test the hypothesis that hormone therapies maybe inducing remissions owing to the fact that increased telomerase expression in this setting delays telomere shortening and disease in these patients.
To this end, we used a mouse model recently generated by us that faithfully recapitulates the bone marrow phenotype observed in aplastic anemia patients 22 . In this model, conditional Trf1 gene deletion specifically in the hematopoietic system causes acute telomere uncapping and persistent activation of a DNA damage response at telomeres, leading to a fast elimination of those HSCs and progenitor cells lacking
Trf1. Because Trf1 deletion is not complete, the remaining non-Trf1 deleted HSCs undergo extra rounds of compensatory proliferation leading to rapid telomere shortening. Thus, incomplete depletion of the stem cell compartment by Trf1 deletion recapitulates the high turnover and hyperproliferation observed in aplastic anemia patients of autoimmune origin, as well as presence of very short telomeres owing to mutations in telomere maintenance genes.
Interestingly, in our mouse model we can experimentally set the frequency of induction of Trf1 mediated stem cell depletion, thus adjusting the rate of progressive telomere shortening and disease onset. In particular, continuous Trf1 deletion leads to rapid telomere shortening and cellular senescence of the progenitor and stem cells in the bone marrow 23 . This in turn leads to bone marrow aplasia and pancytopenia
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.
Here we used this mouse model to examine whether androgen therapy can increase telomerase activity, decelerate telomere attrition and consequently delay the emergence of bone marrow failure.
Methods

Study approval
All experiments including mice were done using protocols approved by the CNIO-
Instituto de Salud Carlos III (CNIO-ISCIII) Ethics Committee for Research and Animal
Welfare (CEIyBA). Mice were treated in accordance to the Spanish laws and the guidelines of the Federation of European Laboratory Animal Science Associations (FELASA).
Mice and animal procedures
All mice were C57/BL6 background and were produced and housed at the specific pathogen-free animal house of the CNIO, Madrid. . MEFs were prepared as described 26 .
Quantitative real-time PCR
Total RNA from tissues was extracted with Qiagen's RNeasy Mini kit, according to the manufacturer's instructions. Before processing, RNA samples were DNaseI treated.
Quantitative real-time PCR was performed using an ABI PRISM 7700 (Applied Biosystems). Primers are listed in Supplementary Table 2 .
Testosterone Elisa
100μl of peripheral blood was extracted at various time points from the same mice.
Serum was isolated and frozen at -80°C until measurement of serum testosterone levels with a Testosterone (mouse/rat) ELISA kit (MyBioSource, MBS494055) according to the manufacturer's protocol.
Blood counts
Peripheral blood was drawn from the facial vein (~50 μl) and collected into anticoagulation tubes (EDTA). Blood counts were determined using an Abacus Junior Vet veterinary hematology analyzer.
Histology
Bone marrow and liver samples were fixed in phosphate-buffered 4% formaldehyde, bones decalcified and embedded in paraffin. Tissue sections (5 μm) were stained with Hematoxylin-Eosin. Immunohistochemistry was performed on deparaffinized tissues sections and processed with the anti-p19 antibodies (sc-32748, Santa Cruz Biotechnology).
Telomere analysis
Q-FISH on tissue sections or metaphase spreads was performed as described
27
. HT-Q-FISH on peripheral blood leukocytes was done using 120-150μl of blood as described 28 . For details see Supplementary Material.
Statistics
Survival curves were analysed using the log-rank (Mantel-Cox) test. Time course experiments were analysed using the Two-way ANOVA test (population doubling assay, HT-Q-FISH, testosterone level). Remaining experiments were analysed using Student's t-test (qPCR, Q-FISH, blood counts, immunohistochemistry). Data are presented as mean ± SEM; P values ≤ 0.05 were considered significant.
Results
Testosterone and estradiol treatment increases Tert expression in vitro
We first addressed whether sex hormone treatment (testosterone and estradiol)
increases Tert expression in murine cells similar to that observed in cultured human cells 20, 21 . To this end, we isolated and cultured whole bone marrow cells and mouse embryonic fibroblasts (MEFs) (E13. Since both testosterone and estradiol could increase Tert expression, and estradiol seemed to be a more potent stimulant, we next tested whether this activation is mediated through the estrogen receptor (ER), as it has been described for primary human hematopoietic cells
21
. We treated bone marrow cells and MEFs simultaneously with testosterone and the ER antagonist 4-hydroxytamoxifen and found that this significantly decreased the testosterone effects in both cell types suggesting that Tert up-regulation is mainly executed through the ER (Figure 1 C-D . In addition, we identified an imperfect palindromic ERE ~2.3kb upstream from the transcriptional start site (Figure 1 G). We did not find an androgen receptor response element consensus sequence within 5kb upstream of Tert. These findings suggest a direct Tert activation via the ER in mice.
Hormone treatment impacts on telomere length but not on proliferation in MEFs
Next, we addressed whether hormone treatment resulted in increased telomere length in MEFs and whether this was mediated by telomerase activity. To this end, we 
In vivo testosterone treatment results in longer telomeres in wild-type mice
To address the effects of hormone treatment in vivo, we first subcutaneously implanted mice with testosterone 90 days slow release pellets and subsequently performed ELISA to check serum testosterone levels at several time points after pellet implantation. We found a more than 20 fold increase in testosterone levels which remained stable over time (Supplementary Figure 2 A ). To test whether this increased testosterone was biologically active, we tested the well-described erythropoietic stimulating effect of androgens 32, 33 . Eight weeks after testosterone pellet implantation, we found significantly elevated erythrocyte counts, increased hematocrit, and increased hemoglobin levels, in the hormone treated mice compared with the untreated controls .
In vivo testosterone treatment significantly rescues survival in a mouse model of aplastic anemia associated with short telomeres
Next, we set out to investigate the potential benefits of androgen therapy in a mouse model of aplastic anemia induced by short telomeres recently generated by us
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. In this mouse model, Trf1 deletion leads to rapid telomere shortening and aplastic anemia onset. To this end, we first generated wild-type irradiated mice, which received either Trf1 lox/lox Mx1-Cre or Trf1 lox/lox Mx1-wt bone marrow transplants. In this experimental setting, Trf1 deletion can be induced specifically in the bone marrow upon treatment with polyinosinic:polycytidylic acid (pI:pC), which will trigger Cre expression in the Trf1 lox/lox Mx1-Cre transplanted bone marrow but not in the Trf1 lox/lox Mx1-wt control.
We hypothesized that in vivo activation of Tert via androgen therapy can antagonize telomere attrition associated to pI:pC induced Trf1 deletion and thus prevent or delay the appearance of aplastic anemia and prolong survival in this mouse model. In conclusion, persistent Trf1 deletion by continually administering pI:pC 2 times per week in our experimental model results in severe stem cell depletion and extreme telomere shortening in the bone marrow thus leading to aplastic anemia. Importantly, this process can be significantly attenuated by androgen therapy.
Next, we performed a different protocol for Trf1 deletion in our mouse model, in which we first induced deletion of Trf1 by pI:pC 3 times per week for a total of 4 weeks and then subjected parts of the mice to androgen therapy (Figure 4 A). Interestingly, this regime resulted in longer overall survival times upon Trf1 deletion (Figure 4 B).
The longer survival times allowed us to perform longitudinal telomere length analysis on peripheral blood leukocytes and follow of telomere dynamics over time in both mouse cohorts
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. As expected, Trf1 deletion resulted in a rapid drop of telomere length in leukocytes as soon as one month after the treatment was started. Importantly, after this initial drop in telomere length, mice receiving androgen therapy were able to maintain a stable telomere length over time, while telomeres continued to shorten in mice that did not receive androgen therapy ( In summary, these data support our hypothesis that androgen therapy counteracts telomere attrition in mice with aplastic anemia owing to Trf1-induced telomere shortening, thus preventing replicative exhaustion of HSCs and the emergence of aplastic anemia.
Discussion
Some aplastic anemia patients have been treated with androgens since the 1950 th and in some of them remission was observed 18, 36 . However, the underlying mechanism for treatment success in some cases but not in others has remained unknown to date. There is growing evidence that sex hormones stimulate telomerase expression 20, 21 . This is of particular importance for those cases of aplastic anemia presenting with very short telomeres, which in turn may be associated to HSC exhaustion.
The findings described here indicate that treatment with androgens increases further that the use of androgen derivates might provide a useful addition to recent treatment protocols in order to prevent replicative exhaustion as a consequence of the underlying autoimmune process in aplastic anemia.
In summary, several lines of evidence suggest that telomerase activation and telomere elongation can be mediated through the action of sex hormones in vivo. Here, we present the first experimental evidence that testosterone therapy in a mouse model of aplastic anemia produced by short telomeres is beneficial for survival and is associated with longer telomere length in bone marrow and peripheral blood cells. Our study warrants further investigation of hormone therapy in humans with aplastic anemia.
Finally, hormone treatment may be extended to treat and/or prevent other disease manifestations associated with short telomeres and replicative exhaustion. 
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To control for potential adverse affects of pI:pC and testosterone we included mice that
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were untreated, treated with testosterone alone or mice without Cre. For details see
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Supplementary Table_1. signal intensity was quantified using Definiens software.
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HT-Q-FISH on peripheral blood leukocytes was done using 120-150 µl blood extracted 
